Establishing a Cost-effective Return of Results to Parents of Boys in VISION-DMD Clinical Trials

Information

  • Research Project
  • 9929267
  • ApplicationId
    9929267
  • Core Project Number
    R44NS095423
  • Full Project Number
    3R44NS095423-03S1
  • Serial Number
    095423
  • FOA Number
    PA-19-217
  • Sub Project Id
  • Project Start Date
    7/1/2019 - 5 years ago
  • Project End Date
    6/30/2020 - 4 years ago
  • Program Officer Name
    CAPORELLO, EMILY LAURA
  • Budget Start Date
    7/1/2019 - 5 years ago
  • Budget End Date
    6/30/2020 - 4 years ago
  • Fiscal Year
    2019
  • Support Year
    03
  • Suffix
    S1
  • Award Notice Date
    7/19/2019 - 5 years ago

Establishing a Cost-effective Return of Results to Parents of Boys in VISION-DMD Clinical Trials

Abstract (Administrative Supplement) In this supplemental project, we will study an innovative and cost-effective approach to returning individual and aggregate, non-genetic clinical trial data to families of boys with Duchenne muscular dystrophy (DMD) participating in vamorolone trials (n=168). The assessment of this approach will involve extensive community stakeholder input and return of individual and aggregate trial data to participants in VBP15-002, 003, and LTE. A centralized, sponsor- initiated design will be utilized for re-consent and connecting patients with their data, using a single coordinator to preserve privacy firewall between patients and industry study teams. Before and following return of data, surveys will be administered to the child?s parents and physicians regarding ethics and logistics. This information will then inform return of data to participants in VBP15-004. The Parent Grant is a SBIR Phase 2 and 2B NINDS award for support of three clinical trials of vamorolone in DMD (VBP15-002 and VBP15-003 [48 patients, 4-7 years; completed]; VBP15-004 [120 patients, 4-7 years, enrollment complete 2019).

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R44
  • Administering IC
    NS
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    109999
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:109999\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
  • Study Section Name
  • Organization Name
    REVERAGEN BIOPHARMA, INC.
  • Organization Department
  • Organization DUNS
    802841069
  • Organization City
    ROCKVILLE
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    208500353
  • Organization District
    UNITED STATES